Phenotypic Space Mapping for Cancer Drug Resistance Trajectories
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly combination therapies, lack rational, quantitative methods for designing drug combinations, leading to resistance and recurrence due to unaddressed cellular redundancies and phenotypic changes, and there is a need for personalized approaches to minimize metastasis and recurrence.
Innovation Solution
A method using a trained artificial neural network to map single-cell 'omics data to a phenotypic space, determining drug therapy trajectories that avoid phenotypes contributing to resistance, optimizing drug combinations to minimize recurrence and metastasis by projecting cancer cells into a multidimensional phenotypic space using deep learning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-cell 'omics data is mapped to phenotypic space using deep learning, then rational and quantitative design of drug combinations is enabled, but computational complexity and data processing requirements increase
Solution Approach 1:
The computational system is segmented into modular components: data preprocessing module, neural network mapping module, trajectory determination module, and efficacy classification module. This segmentation allows complex computations to be broken down into manageable, independent tasks that can be processed sequentially, reducing overall system complexity while maintaining reliability.
Solution Approach 2:
Phenotypic space serves as an intermediary representation layer between raw single-cell 'omics data and drug therapy outcomes. The deep learning network maps high-dimensional genomic data into this intermediate phenotypic space, where trajectories can be analyzed and drug combinations designed rationally, simplifying the connection between genotype and therapeutic response.
2Reliability
If drug therapy trajectories are determined in phenotypic space to avoid resistance phenotypes, then recurrence and metastasis are minimized, but treatment planning complexity increases
Solution Approach 1:
The system performs preliminary mapping of cancer cells into phenotypic space and determines optimal therapy trajectories before actual treatment administration. By pre-calculating trajectories that avoid resistance-associated phenotypes (such as stem cell or mesenchymal states), the system enables proactive treatment planning that prevents resistance development rather than reacting to it afterward.
Solution Approach 2:
The system incorporates feedback mechanisms where trajectory predictions inform treatment decisions, and observed cellular responses feed back into the model for refinement. The neural network learns from training data about how different drug combinations affect phenotypic trajectories, using this feedback to improve future treatment recommendations and avoid phenotypes associated with resistance.
3Measurement precision
If multidimensional phenotypic space is used to visualize cellular changes, then quantitative assessment of drug efficacy is improved, but data processing and analysis requirements increase
Solution Approach 1:
The system transforms single-cell 'omics data into multidimensional phenotypic space, adding dimensional context to cellular state representation. Each dimension corresponds to a specific phenotypic attribute, allowing quantitative assessment of drug effects across multiple dimensions simultaneously. This dimensional transformation enables precise measurement of efficacy while the neural network handles the computational burden of processing high-dimensional data.
Data Source
AI summary
Systems and methods are disclosed for mapping single-cell 'omics data in a phenotypic space. The method comprises reading single-cell 'omics data; providing the single-cell 'omics data to a trained artificial neural network, the trained artificial neural network mapping the single-cell 'omics data to a point in a phenotypic space; determining a trajectory of the point within the phenotypic space based on at least one drug therapy; and classifying an efficacy of the at least one drug therapy based on the trajectory.